Immix Biopharma Inc
IMMX
查看详细走势图
5.810USD
+0.090+1.57%
收盘 12/22, 16:00（美东）报价延迟15分钟
191.94M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.57%
5天
-6.37%
1月
+34.18%
6月
+159.38%
今年开始到现在
+164.09%
1年
+167.74%
查看详细走势图
TradingKey Immix Biopharma Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值低估，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Immix Biopharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
12.000
目标均价
+95.12%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Immix Biopharma Inc亮点
亮点风险
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值低估
公司最新PE估值-4.34，处于3年历史低位
机构减仓
最新机构持股2.76M股，环比减少41.12%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值698.54K
活跃度增加
近期活跃度增加，过去20天平均换手率0.15
Immix Biopharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Immix Biopharma Inc简介
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
公司代码IMMX
公司Immix Biopharma Inc
CEORachman (Ilya)
网址https://immixbio.com/
常见问题
Immix Biopharma Inc(IMMX)的当前股价是多少？
Immix Biopharma Inc(IMMX)的当前股价是 5.810。
Immix Biopharma Inc的股票代码是什么？
Immix Biopharma Inc的股票代码是IMMX。
Immix Biopharma Inc股票的52周最高点是多少？
Immix Biopharma Inc股票的52周最高点是7.730。
Immix Biopharma Inc股票的52周最低点是多少？
Immix Biopharma Inc股票的52周最低点是1.340。
Immix Biopharma Inc的市值是多少？
Immix Biopharma Inc的市值是191.94M。
Immix Biopharma Inc的净利润是多少？
Immix Biopharma Inc的净利润为-21.61M。
现在Immix Biopharma Inc(IMMX)的股票是买入、持有还是卖出？
根据分析师评级，Immix Biopharma Inc(IMMX)的总体评级为买入，目标价格为12.000。
Immix Biopharma Inc(IMMX)股票的每股收益（EPS TTM）是多少
Immix Biopharma Inc(IMMX)股票的每股收益（EPS TTM）是-0.775。
相关品种
